Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β(2)-agonist fixed-dose combination: RE(2)SPOND rationale and study design

BACKGROUND: Roflumilast, a once-daily, selective phosphodiesterase-4 inhibitor, reduces the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. The RE(2)SPOND study is examining whether roflumilast, when added to an inhaled corti...

Descripción completa

Detalles Bibliográficos
Autores principales: Rennard, Stephen I, Martinez, Fernando J, Rabe, Klaus F, Sethi, Sanjay, Pizzichini, Emilio, McIvor, Andrew, Siddiqui, Shahid, Anzueto, Antonio, Zhu, Haiyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994799/
https://www.ncbi.nlm.nih.gov/pubmed/27574416
http://dx.doi.org/10.2147/COPD.S109661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994799/
https://www.ncbi.nlm.nih.gov/pubmed/27574416
http://dx.doi.org/10.2147/COPD.S109661

Ejemplares similares